

**Highly Diastereo- and Enantioselective Mannich Reaction of Lactones with
N-Boc-Aldimines Catalyzed by Bifunctional Rosin-Derived Amine Thiourea
Catalysts**

Xianxing Jiang,^{a,b} Dan Fu,^a Gen Zhang,^a Yiming Cao,^a Luping Liu,^a Jingjing Song,^a and Rui Wang^{*a,b}

^a State Key Laboratory of Applied Organic Chemistry, Institute of Biochemistry and Molecular Biology, Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Lanzhou University, Lanzhou 730000, China

^b Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong

E-mail: wangrui@lzu.edu.cn and bcrwang@polyu.edu.hk

Supporting information

Contents	S1
1.0 General Methods	S2
2.0 General Procedure and data for synthesis of lactones	S2
3.0 General Procedure for catalytic asymmetric Mannich reaction	S3
4.0 Characterization data	S4
5.0 References	S12
6.0 X-Ray structure of 5g	S12
7.0 Copies of HPLC spectra of racemic /chiral products	S13
8.0 Copies of NMR spectra of products	S31

1.0 General Methods: All reactions were carried out under an argon atmosphere condition unless otherwise noted and solvents were dried according to established procedures. Reactions were monitored by thin layer chromatography (TLC), column chromatography purifications were carried out using silica gel GF254. Proton nuclear magnetic resonance (^1H NMR) spectra were recorded on Brucker 300 MHz spectrometer in CDCl_3 unless otherwise noted and carbon nuclear magnetic resonance (^{13}C NMR) spectra were recorded on Brucker 300 MHz spectrometer in CDCl_3 using tetramethylsilane (TMS) as internal standard unless otherwise noted. Data are presented as follows: chemical shift, integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, cm = complex multiplet) and coupling constant in Hertz (Hz). Infrared (IR) spectra were recorded on a FT-IR spectrometer. HR-MS was measured with an APEX II 47e mass spectrometer. Melting points were measured on an XT-4 melting point apparatus and were uncorrected. The ee values determination was carried out using chiral high-performance liquid chromatography (HPLC) with Daicel Chiracel AD-H and OJ-H column on Waters with a 2996 UV-detector and the dr values determined by 300 Hz ^1H NMR and HPLC.


Abbreviations used: EtOAc- ethyl acetate, THF- tetrahydrofuran, *i*PrOH- isopropanol, CH_2Cl_2 - dichloromethane, LDA- Lithium diisopropylamide.

Materials: Dehydroabietic amine, 3,5-bis(trifluoromethyl)phenyl isothiocyanate, β -ketoesters, LDA and α -acetyl- γ -butyrolactone were commercially available from Acros and Aldrich. Thiourea catalysts were synthesized according to the literature procedures.^{1,2}

2. General procedure for synthesis of lactones 4b-4d.


To a solution of LDA (25.0 mmol) in THF (30 mL) was added γ -butyrolactone (0.77 mL, 10.0 mmol) at -78 °C under an argon atmosphere and the mixture was stirred for 1 h at the same temperature. Then, benzoyl chloride (1.28 mL, 11.0 mmol) was added over a period of 30 min at -78 °C and stirring was continued for 15 min. The reaction mixture was diluted with 1 N HCl and extracted with ethyl acetate. The combined organic extracts were washed with brine and dried over Na_2SO_4 . Evaporation of solvents and purification of the residual crude products by column chromatography on silica gel (hexane/ ethyl acetate=6:1 as eluent) gave α -benzoyl- γ -butyrolactone **4b** in 80% yield: 1.52 g.

4b: 3-benzoyldihydrofuran-2(3H)-one




¹H NMR (300 MHz, CDCl₃): δ 8.07-8.10(m, 2 H), 7.49-7.66(m, 3 H), 4.39-4.61(m, 3 H), 2.81-2.92(m, 1 H), 2.46-2.58(m, 1 H); ¹³C NMR (75 MHz, CDCl₃): δ 193.1, 172.9, 135.2, 134.1, 129.5, 128.8, 67.8, 48.0, 26.0. ESI-MS: *m/z* 191 [M⁺].

4c: 3-benzoyltetrahydro-2H-pyran-2-one



¹H NMR (300 MHz, CDCl₃): δ 7.53-7.56(m, 2 H), 7.43-7.46(m, 3 H), 4.37-4.41(m, 2 H), 2.54-2.59(m, 2 H), 1.85-1.88(m, 2 H); ¹³C NMR (75 MHz, CDCl₃): δ 173.2, 134.3, 130.2, 128.2, 94.3, 69.5, 24.4, 23.1. ESI-MS: *m/z* 205 [M⁺].

4d: 3-propionyldihydrofuran-2(3H)-one



¹H NMR (300 MHz, CDCl₃): δ 4.29-4.44(m, 2 H), 3.67-3.73(dd, *J* = 6.6 Hz, 9.3 Hz, 1 H), 2.99-3.13(m, 1 H), 2.73-2.85(m, 1 H), 2.38-2.66(m, 1 H), 2.25-2.35(m, 1 H), 1.11(t, *J* = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 203.0, 172.9, 67.6, 52.0, 35.6, 24.0, 7.4. ESI-MS: *m/z* 143 [M⁺].

3.0 General procedure for the catalytic asymmetric Mannich reaction.


Method A: To a stirred solution of **L2** (0.015 mmol, 15 mol %), *N*-Boc-aldimine (0.1 mmol) in dry toluene (1.0 mL) under an argon atmosphere, ethyl 2-oxocyclopentanecarboxylate (0.12 mmol) was added over a period of 15 min at -60 °C. The solution was stirred at -60 °C for 12 h. After the reaction was completed (monitored by TLC), the resulting mixture was concentrated under reduced pressure and the residue was purified through column chromatography on silica gel (eluent, ethyl acetate / hexane 1:8) to give the optical pure product. The enantiomeric purity of the product was determined by using HPLC and the dr values determined by ¹H NMR and HPLC.

Method B: To a stirred solution of **L2** (0.015 mmol, 15 mol %), *N*-Boc-aldimine (0.1 mmol) in dry toluene (1.0 mL) under an argon atmosphere, the lactone (0.12 mmol) was added over a period

of 15 min at -60 °C. The solution was stirred at -60 °C for 12 h. After the reaction was completed (monitored by TLC), the resulting mixture was concentrated under reduced pressure and the residue was purified through column chromatography on silica gel (eluent, ethyl acetate / hexane 1:10), and affording the products were dissolved in diethyl ether. After filtration and the solvent was removed at reduced pressure to give the pure products. The enantiomeric purity of the product was determined by using HPLC and the dr values determined by ¹H NMR and HPLC.

4.0 Characterization data


3a: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(phenyl)methyl)-2-oxocyclopentane carboxylate



White solid, mp 109 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.25-7.32(m, 5 H), 5.92(br, 1 H), 5.21(d, J = 9.6 Hz, 1 H), 4.11-4.20(m, 2 H), 2.48-2.57(m, 1 H), 2.32-2.40(m, 2 H), 1.83-2.05(m, 3 H), 1.39(s, 9 H), 1.19(t, J = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 211.2, 155.2, 138.5, 128.3, 128.2, 127.7, 79.7, 64.9, 61.8, 55.8, 37.6, 30.6, 28.3, 18.9, 13.9. IR: 3363, 2977, 2932, 1751, 1721, 1700, 1497, 1366, 1230, 1168, 1024, 706 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₂₀H₂₇NO₅ +NH₄⁺: 379.2227; found: 379.2231, 1.1 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 2/98, 0.8 mL/min, 212 nm.) Retention time: t_{major} = 31.01 min, t_{minor} = 77.09 min, ee = 99 %.

3b: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(naphthalen-1-yl)methyl)-2-oxocyclopentane carboxylate




White solid, mp 136 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.28(d, J = 8.4 Hz, 1 H), 7.85(d, J = 7.8 Hz, 1 H), 7.79(d, J = 10.5 Hz, 1 H), 7.63(d, J = 7.2 Hz, 1 H), 7.37-7.58(m, 3 H), 6.02(d, J = 10.2 Hz, 1 H), 5.85(d, J = 9.9 Hz, 1 H), 4.03-4.11(dd, J = 7.2 Hz, 14.1 Hz, 2 H), 2.34-2.79(m, 3 H), 1.91-2.21(m, 3 H), 1.41(s, 9 H), 1.03(t, J = 6.9 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 211.9, 155.6, 135.0, 133.9, 128.8, 128.6, 126.6, 125.7, 125.6, 125.0, 123.6, 79.8, 64.7, 61.6, 50.5, 37.8,

33.1, 28.3, 19.1, 13.7. IR: 3421, 2976, 2932, 1750, 1714, 1567, 1493, 1368, 1230, 1166, 1025, 782 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₂₄H₂₉NO₅ +NH₄⁺: 429.2384; found: 429.2391, 1.6ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 2/98, 1.0 mL/min, 222 nm.) Retention time: t_{major} = 14.87 min, t_{minor} = 27.94 min, ee = 97 %.


3c: (S)-ethyl 1-((R)-(tert-butoxycarbonylamino)(2-fluorophenyl)methyl)-2-oxocyclopentane carboxylate



Colorless needles, mp 120-121 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.49(dt, *J* = 1.8 Hz, 7.8 Hz, 1 H), 7.22-7.29(m, 1 H), 6.99-7.12(m, 2 H), 6.22(d, *J* = 9.6 Hz, 1 H), 5.56(d, *J* = 9.9 Hz, 1 H), 4.08-4.19(m, 2 H), 2.29-2.55(m, 3 H), 1.96-2.12(m, 3 H), 1.39(s, 9 H), 1.19(t, *J* = 6.9 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 210.8, 169.4, 162.1, 158.8, 155.2, 130.2, 130.1, 129.5, 129.4, 124.4, 124.3, 115.6, 115.3, 79.8, 64.8, 61.8, 49.2, 37.2, 30.6, 28.2, 18.8, 13.9. IR: 3441, 2977, 2933, 1753, 1717, 1493, 1459, 1367, 1231, 1168, 1023, 762 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₂₀H₂₆FNO₅ +NH₄⁺: 397.2133; found: 397.2142, 2.3ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 2/98, 1.0 mL/min, 210 nm.) Retention time: t_{major} = 15.24 min, t_{minor} = 19.73 min, ee = 92 %.


3d: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(3-methoxyphenyl)methyl)-2-oxocyclopentane carboxylate



Colorless solid, mp 128-129 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.24(t, *J* = 8.1 Hz, 1 H), 6.88(m, 2 H), 6.78-6.81(m, 1 H), 5.85(br, 1 H), 5.22(d, *J* = 9.6 Hz, 1 H), 4.09-4.17(m, 2 H), 3.78(s, 3 H), 2.47-2.56(m, 1 H), 2.29-2.32(m, 2 H), 1.91-2.05(m, 3 H), 1.39(s, 9 H), 1.20(t, *J* = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ 211.1, 159.5, 155.2, 129.3, 120.5, 113.9, 113.2, 79.8, 64.9, 61.9, 55.2, 37.7, 28.3, 18.9, 13.9. IR: 3363, 2975, 2929, 1751, 1720, 1700, 1494, 1385, 1231, 1167, 1044, 782 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₂₁H₂₉NO₆ +NH₄⁺: 409.2333; found: 409.2325, 2.0ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 2/98, 1.0 mL/min, 215 nm.) Retention time: $t_{\text{major}} = 39.37$ min, $t_{\text{minor}} = 101.46$ min, ee=96 %.


5a: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate



Colorless needles, mp 116-117 °C. ^1H NMR (300 MHz): δ 7.34(m, 5 H), 5.79(d, $J=8.7$ Hz, 1 H), 5.01(d, $J=9.9$ Hz, 1 H), 3.99(dd, $J=7.8$ Hz, 16.5 Hz, 1 H), 3.59(m, 1 H), 2.90 (m, 1 H), 2.49(s, 3 H), 2.03-2.13(m, 1 H), 1.39(s, 9 H); ^{13}C NMR (75 MHz): δ 173.2, 154.6, 128.8, 128.4, 127.2, 80.8, 66.9, 66.1, 56.3, 28.2, 28.1, 25.4. IR: 3341, 2977, 2926, 1761, 1716, 1522, 1456, 1368, 1246, 1165, 1025, 704 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_5 + \text{NH}_4^+$: 351.1914; found: 351.1918, 1.1 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 20/80, 1.0 mL/min, 215 nm.) Retention time: $t_{\text{major}} = 6.65$ min, $t_{\text{minor}} = 15.82$ min, ee=91 %.


5b: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(p-tolyl)methylcarbamate



Colorless needles, mp 149 °C. ^1H NMR (300 MHz): δ 7.14-7.27(m, 4 H), 5.77(d, $J=9.3$ Hz, 1 H), 4.95(d, $J=6.9$ Hz, 1 H), 3.96(dd, $J=8.1$ Hz, 16.2 Hz, 1 H), 3.60-3.62(m, 1 H), 2.85-2.93(m, 1 H), 2.48(s, 3 H), 2.33(s, 3 H), 2.04-2.14(m, 1 H), 1.39(s, 9 H); ^{13}C NMR (75 MHz): δ 173.2, 154.5, 138.2, 144.0, 129.5, 127.1, 80.7, 66.9, 66.1, 56.2, 28.2, 25.4, 24.3, 20.9. IR: 3342, 2979, 2926, 1761, 1715, 1515, 1455, 1368, 1246, 1164, 1025, 733 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_5 + \text{NH}_4^+$: 365.2071; found: 365.2080, 2.5 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 0.8 mL/min, 215 nm.) Retention time: $t_{\text{major}} = 16.05$ min, $t_{\text{minor}} = 24.60$ min, ee=99 %.

5c: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(o-tolyl)methylcarbamate




Colorless needles, mp 126. ^1H NMR (300 MHz): δ 7.56(s, 1 H), 7.19-7.26(m, 3 H), 5.79(d, $J=9.9$

Hz, 1 H), 5.06(d, $J=9.0$ Hz, 1 H), 4.01-4.09(m, 2 H), 2.91-2.95(m, 1 H), 2.55-2.62(m, 1 H), 2.49(s, 3 H), 2.23(s, 3 H), 1.38(s, 9 H); ^{13}C NMR (75 MHz): δ 173.8, 136.9, 136.1, 131.4, 128.4, 127.5, 126.3, 80.6, 66.9, 65.9, 51.9, 29.7, 28.2, 26.3, 20.0. IR: 3402, 2976, 2926, 1759, 1714, 1505, 1458, 1368, 1244, 1164, 1029, 754 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_5+\text{NH}_4^+$: 365.2071; found: 365.2076, 1.4ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 212 nm.) Retention time: $t_{\text{major}}=11.24$ min, $t_{\text{minor}}=23.72$ min, ee=93 %.


5d: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-methoxyphenyl)methylcarbamate



Colorless solid, mp 180-181 °C. ^1H NMR (300 MHz): δ 7.30-7.40(m, 2 H), 6.96(dd, $J=7.5$ Hz, 15.9 Hz, 2 H), 5.89-5.96(m, 2 H), 3.94-3.97(m, 1 H), 3.87(s, 3 H), 3.82-3.84(m, 1 H), 2.86-2.94(m, 1 H), 2.45(s, 3 H), 2.14-2.34(m, 1 H), 1.39(s, 9 H); ^{13}C NMR (75 MHz): δ 173.5, 157.3, 135.9, 131.4, 129.8, 124.4, 121.4, 111.4, 80.2, 67.2, 66.3, 55.9, 55.4, 28.3, 26.1, 25.9. IR: 3354, 2979, 2927, 2855, 1760, 1713, 1495, 1370, 1246, 1164, 1028, 735 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_6+\text{NH}_4^+$: 381.2020; found: 381.2012, 2.1ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 224 nm.) Retention time: $t_{\text{major}}=16.10$ min, $t_{\text{minor}}=24.84$ min, ee=88 %.

5e: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(3-methoxyphenyl)methylcarbamate




Colorless needs, mp 159 °C. ^1H NMR (300 MHz): δ 7.24-7.29(m, 1 H), 6.84-6.89(m, 3 H), 5.80(d, $J=9.6$ Hz, 1 H), 4.97(d, $J=6.9$ Hz, 1 H), 4.03(dd, $J=8.1$ Hz, 16.2 Hz, 1 H), 3.79(s, 3 H), 3.64-3.67(m, 1 H), 2.88(m, 1 H), 2.49(s, 3 H), 2.04-2.13(m, 1 H), 1.39(s, 9H); ^{13}C NMR (75 MHz): δ 200.8, 173.2, 159.9, 154.6, 138.6, 129.9, 119.2, 113.9, 112.9, 80.8, 66.9, 66.2, 56.2, 55.3, 28.2, 25.4, 24.3. IR: 3346, 2978, 2931, 1761, 1716, 1518, 1493, 1368, 1248, 1164, 1026, 782 cm^{-1} .

HRMS-ESI (*m/z*): calcd for C₁₉H₂₅NO₆+NH₄⁺: 381.2020; found: 381.2025, 1.3ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 0.8 mL/min, 215 nm.) Retention time: t_{major} = 24.18 min, ee=99 %.


5f: *tert*-butyl (S)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(m-tolyl)methylcarbamate



Colorless solid, mp 139-140 °C. ¹H NMR (300 MHz): δ 7.11-7.27(m, 4 H), 5.79(d, *J*=9.6 Hz, 1 H), 4.99(br, 1 H), 3.99(dd, *J*=8.1 Hz, 16.2 Hz, 1 H), 3.60-3.61(m, 1 H), 2.89(m, 1 H), 2.49(s, 3 H), 2.34(s, 3 H), 2.07-2.11(m, 1 H), 1.39(s, 9 H); ¹³C NMR (75 MHz): δ 173.2, 154.6, 138.6, 129.2, 128.7, 128.0, 124.1, 80.7, 66.9, 66.1, 56.3, 28.2, 25.4, 24.2, 21.5. IR: 3350, 2923, 2853, 1757, 1714, 1518, 1456, 1369, 1245, 1163, 1027, 732 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₁₉H₂₅NO₅+NH₄⁺: 365.2071; found: 365.2065, 1.6ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 224 nm.) Retention time: t_{major} = 9.74 min, t_{minor} = 27.86 min, ee=82 %.


5g: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-bromophenyl)methylcarbamate



Colorless solid, mp 169 °C. ¹H NMR (300 MHz): δ 7.57-7.60(d, *J*=8.1 Hz, 1 H), 7.43-7.46(d, *J*=7.8 Hz, 1 H), 7.32-7.37(t, *J*=7.2 Hz, 1 H), 7.17-7.22(m, 1 H), 7.03(d, *J*=9.9 Hz, 1 H), 6.08(d, *J*=9.9 Hz, 1 H), 3.95-4.02(m, 2 H), 2.49(s, 3 H), 2.39-2.44(m, 1 H), 2.13-2.26(m, 1 H), 1.38(s, 9 H); ¹³C NMR (75 MHz): δ 203.5, 175.6, 136.9, 132.9, 130.1, 129.0, 128.8, 125.5, 80.4, 65.7, 65.1, 54.2, 29.7, 28.2, 25.3. IR: 3409, 2978, 2926, 1766, 1712, 1590, 1494, 1366, 1221, 1167, 1029, 758 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₁₈H₂₂BrNO₅+NH₄⁺: 429.1020; found: 429.1028, 1.9ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 0.8 mL/min, 215 nm.) Retention time: t_{minor} = 15.06 min, t_{major} = 17.78 min, ee=98 %.


5h: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-fluorophenyl)methylcarbamate



Colorless solid, mp 127-128 °C. ^1H NMR (300 MHz): δ 7.47-7.49(m, 1 H), 7.31-7.34(m, 1 H), 7.04-7.17(m, 2 H), 5.95(d, $J=10.5$ Hz, 1 H), 5.35(d, $J=8.4$ Hz, 1 H), 3.96-4.03(m, 2 H), 2.95-3.02(m, 1 H), 2.44(s, 3 H), 2.19-2.28(m, 1 H), 1.39(s, 9 H); ^{13}C NMR (75 MHz): δ 172.9, 159.3, 154.8, 131.7, 130.5, 130.4, 124.9, 123.8, 116.5, 116.1, 80.7, 67.2, 66.5, 54.6, 28.2, 28.1, 25.7, 25.5. IR: 3365, 2979, 2929, 1767, 1716, 1493, 1457, 1368, 1246, 1164, 1023, 763 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{18}\text{H}_{22}\text{FNO}_5 + \text{NH}_4^+$: 369.1820; found: 369.1823, 0.8 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 10/90, 0.8 mL/min, 215 nm.) Retention time: $t_{\text{major}} = 12.68$ min, $t_{\text{minor}} = 23.46$ min, ee=81 %.


5i: *tert*-butyl (S)-((R)-3-acetyl-2-oxotetrahydrofuran-3-yl)(4-chlorophenyl)methylcarbamate



White solid, mp 144-145 °C. ^1H NMR (300 MHz): δ 7.27-7.36(m, 4 H), 5.77(d, $J=8.1$ Hz, 1 H), 4.94(br, 1 H), 4.03(dd, $J=8.4$ Hz, 16.8 Hz, 1 H), 3.74-3.78(m, 1 H), 2.86-2.92(m, 1 H), 2.46(s, 3 H), 1.99-2.09(m, 1 H), 1.39(s, 9 H); ^{13}C NMR (75 MHz): δ 173.1, 154.6, 135.7, 134.5, 129.1, 128.8, 81.2, 66.9, 66.4, 55.9, 28.3, 25.5, 24.5. IR: 3340, 2980, 2928, 1761, 1716, 1519, 1494, 1369, 1246, 1164, 1019, 733 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{18}\text{H}_{22}\text{ClNO}_5 + \text{NH}_4^+$: 385.1525; found: 385.1518, 1.8 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel OJ-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 224 nm.) Retention time: $t_{\text{minor}} = 11.24$ min, $t_{\text{major}} = 15.46$ min, ee=75 %.

5j: *tert*-butyl (R)-((R)-3-acetyl-2-oxotetrahydrofuran-3-yl)(thiophen-2-yl)methylcarbamate




Colorless solid, mp 174-175 °C. ^1H NMR (300 MHz): δ 7.17-7.19(m, 1 H), 6.90-6.97(m, 2 H), 6.01(d, $J=9.3$ Hz, 1 H), 4.82(d, $J=9.3$ Hz, 1 H), 3.86-4.03(m, 2 H), 2.79-2.82(m, 1 H), 2.39(s, 3 H), 2.08-2.18(m, 1 H), 1.35(s, 9 H); ^{13}C NMR (75 MHz): δ 173.0, 154.5, 127.6, 126.8, 126.2, 125.3, 81.1, 67.5, 66.4, 53.1, 29.7, 28.2, 25.4. IR: 3306, 2922, 2852, 1749, 1715, 1682, 1526, 1367, 1248,

1162, 1024, 732 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₁₆H₂₁NO₅S+NH₄⁺: 357.1479; found: 357.1471, 2.2ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel OJ-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 236 nm.) Retention time: t_{major} = 13.39 min, t_{minor} = 14.72 min, ee=93 %.


5k: *tert*-butyl (S)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(furan-3-yl)methylcarbamate



White solid, mp 130 °C. ¹H NMR (300 MHz): δ 7.39(d, *J*=1.8 Hz, 2 H), 6.35(s, 1 H), 5.75(d, *J*=9.3 Hz, 1 H), 4.69(br, 1 H), 4.08(dd, *J*=5.4 Hz, 9.3 Hz, 2 H), 2.81-2.89(m, 1 H), 2.43(s, 3 H), 2.11-2.21 (m, 1 H), 1.42(s, 9 H); ¹³C NMR (75 MHz): δ 173.4, 154.7, 143.9, 140.6, 109.4, 80.9, 66.9, 66.4, 49.9, 28.2, 25.6, 25.0. IR: 3412, 3005, 2924, 2854, 1745, 1714, 1524, 1423, 1363, 1223, 1165, 531 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₁₆H₂₁NO₆+NH₄⁺: 341.1707; found: 341.1713, 1.8ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel OJ-H, *i*-PrOH/ Hexane = 10/90, 1.0 mL/min, 212 nm.) Retention time: t_{minor} = 14.24 min, t_{major} = 20.24 min, ee=87 %.


6a: *tert*-butyl (S)-((*R*)-3-benzoyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate



White solid, mp 152 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.86(d, *J* = 7.2 Hz, 2 H), 7.48-7.62(m, 3 H), 7.35-7.37(m, 5 H), 6.65(d, *J* = 9.0 Hz, 1 H), 5.64(d, *J* = 9.3 Hz, 1 H), 4.14(dd, *J* = 8.4 Hz, 15.9 Hz, 1 H), 3.51-3.58(m, 1 H), 2.76-2.85(m, 1 H), 2.49-2.58(m, 1 H), 1.29(s, 9 H); ¹³C NMR (75 MHz, CDCl₃): δ 196.9, 176.1, 154.3, 137.2, 134.9, 133.2, 128.9, 128.8, 128.6, 128.3, 79.7, 65.6, 63.1, 57.3, 31.0, 28.1. IR: 3419, 2978, 2925, 1764, 1715, 1674, 1496, 1369, 1246, 1169, 1031, 701 cm⁻¹. HRMS-ESI (*m/z*): calcd for C₂₃H₂₅NO₅ +NH₄⁺: 413.2071; found: 413.2078, 1.7ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 20/80, 1.0 mL/min, 247 nm.) Retention time: t_{minor} = 14.37 min, t_{major} = 21.82 min, ee=57 %.


7a: *tert*-butyl (S)-((*R*)-3-benzoyl-2-oxotetrahydro-2H-pyran-3-yl)(phenyl)methylcarbamate



White solid, mp 146-147 °C. ^1H NMR (300 MHz, CDCl_3): δ 7.74(d, $J = 7.5$ Hz, 2 H), 7.19-7.51(m, 8 H), 6.84(d, $J = 9.9$ Hz, 1 H), 5.28(d, $J = 9.6$ Hz, 1 H), 4.15-4.22(m, 1 H), 3.85-3.93(m, 1 H), 2.42-2.49(m, 1 H), 1.92-2.01(m, 1 H), 1.64-1.74(m, 1 H), 1.36-1.42(m, 1 H), 1.50(s, 9 H); ^{13}C NMR (75 MHz, CDCl_3): δ 198.6, 170.0, 153.3, 137.1, 135.7, 131.5, 127.9, 127.6, 127.2, 126.9, 78.4, 68.2, 63.4, 59.1, 28.3, 27.2, 19.0. IR: 3422, 2963, 2927, 2855, 2254, 1712, 1487, 1366, 1233, 1166, 910, 733 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{24}\text{H}_{27}\text{NO}_5 + \text{H}^+$: 410.1962; found: 410.1968, 1.5 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 15/85, 1.0 mL/min, 245 nm.) Retention time: $t_{\text{minor}} = 14.78$ min, $t_{\text{major}} = 27.84$ min, ee=30 %.

8a: *tert*-butyl (S)-((R)-2-oxo-3-propionyltetrahydrofuran-3-yl)(phenyl)methylcarbamate



Colorless solid, mp 131 °C. ^1H NMR (300 MHz, CDCl_3): δ 7.57(m, 5 H), 6.64(d, $J = 9.3$ Hz, 1 H), 5.31(d, $J = 9.6$ Hz, 1 H), 4.02(dd, $J = 8.4$ Hz, 16.8 Hz, 1 H), 3.67-3.68(m, 1 H), 2.65-2.88(m, 2 H), 2.32-2.40(m, 1 H), 2.16-2.26(m, 1 H), 1.29(s, 9 H), 1.12(t, $J = 6.9$ Hz, 3 H); ^{13}C NMR (75 MHz, CDCl_3): δ 206.1, 176.1, 154.7, 137.2, 128.9, 128.6, 128.1, 80.1, 65.6, 64.1, 56.8, 31.9, 30.2, 28.2, 7.7. IR: 3425, 2986, 2915, 1773, 1695, 1500, 1457, 1371, 1216, 1168, 1026, 710 cm^{-1} . HRMS-ESI (m/z): calcd for $\text{C}_{19}\text{H}_{25}\text{NO}_5 + \text{NH}_4^+$: 365.2056; found: 365.2064, 1.9 ppm.

Major diastereomer: ee was determined by HPLC analysis (Chiralcel AD-H, *i*-PrOH/ Hexane = 20/80, 1.0 mL/min, 212 nm.) Retention time: $t_{\text{major}} = 6.11$ min, $t_{\text{minor}} = 11.0$ min, ee=90 %.


5.0 References.

- (1). T. Okino, Y. Hoashi, T. Furukawa, X. N. Xu and Y. Takemoto, *J. Am. Chem. Soc.* 2005, **127**, 119.
- (2). (a) X. X. Jiang, Y. F. Zhang, A. S. C. Chan and R. Wang, *Org. Lett.* 2009, **11**, 153; (b) X. X. Jiang, Y. F. Zhang, X. Liu, G. Zhang, L. H. Lai, L. P. Wu, J. N. Zhang and R. Wang, *J. Org. Chem.* 2009, **74**, 5562.

6.0 X-Ray structure of 5g



The X-ray crystal structure of 5g: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-bromophenyl)methylcarbamate

(The CCDC deposition number : CCDC 760713.)




7.0 Copies of HPLC spectra of racemic /chiral products.

3a: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(phenyl)methyl)-2-oxocyclopentane carboxylate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	25.399	1061303	7.48	25980	bb	Unknown
2	30.055	1014769	7.15	22761	bb	Unknown
3	32.213	6750276	47.58	105534	bb	Unknown
4	72.826	5361809	37.79	49218	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	25.167	431142	1.13	13739	bb	Unknown
2	31.007	37227751	97.89	540569	bb	Unknown
3	77.091	372937	0.98	4206	bb	Unknown

3b: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(naphthalen-1-yl)methyl)-2-oxocyclopentane carboxylate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.866	14109290	42.17	493075	bb	Unknown
2	18.572	2581844	7.72	75899	bb	Unknown
3	22.381	2616502	7.82	57393	bb	Unknown
4	27.652	14149777	42.29	315978	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.866	33703631	95.26	1315317	bb	Unknown
2	18.647	1108305	3.13	41573	bb	Unknown
3	27.940	567208	1.60	16801	bb	Unknown

3c: (S)-ethyl 1-((R)-(tert-butoxycarbonylamino)(2-fluorophenyl)methyl)-2-oxocyclopentane carboxylate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	15.210	57570022	43.77	1321898	bb	Unknown
2	17.126	9296493	7.07	291556	bb	Unknown
3	19.393	59460051	45.21	1260556	bb	Unknown
4	25.653	5191613	3.95	97984	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	15.237	13924307	95.83	513347	bb	Unknown
2	19.726	605354	4.17	22257	bb	Unknown

3d: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(3-methoxyphenyl)methyl)-2-oxocyclopentanecarboxylate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	30.370	1788198	6.23	37998	bb	Unknown
2	37.670	12627795	43.98	153125	bb	Unknown
3	51.234	1672586	5.82	17154	bb	Unknown
4	99.152	12626779	43.97	72318	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	32.118	363551	1.26	8009	bb	Unknown
2	39.370	27864087	96.51	326258	bb	Unknown
3	101.457	643995	2.23	5425	bb	Unknown

5a: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	11.629	7714918	49.05	383352	bb	Unknown
2	32.465	8013356	50.95	145952	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	6.654	3104104	95.51	257631	bb	Unknown
2	15.820	146033	4.49	6332	bb	Unknown

5b: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(p-tolyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	16.232	56140855	55.37	1677617	bb	Unknown
2	24.265	45242931	44.63	1050736	bb	Unknown




Entry	Retention Time	Area	Area(%)	Height	Int Type	Peak Type
1	16.047	19786203	100.00	579181	bb	Unknown
2	24.600	805	0.00	-43	bb	Unknown

5c: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(o-tolyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	10.613	10578988	50.83	383516	bb	Unknown
2	22.410	10234550	49.17	193316	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	11.240	11901811	96.57	482065	bb	Unknown
2	23.719	422183	3.43	9442	bb	Unknown

5d: *tert*-butyl ((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-methoxyphenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	15.845	3305170	49.96	106684	bb	Unknown
2	24.546	3310453	50.04	72198	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	16.097	16704411	94.12	511686	bb	Unknown
2	24.838	1043062	5.88	25790	bb	Unknown

5e: *tert*-butyl ((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(3-methoxyphenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	22.196	1804146	50.69	60266	bb	Unknown
2	25.535	1755228	49.31	39173	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	24.182	22300762	100.00	454724	bb	Unknown

5f: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(m-tolyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	9.323	8579092	49.97	430607	bb	Unknown
2	27.458	8589667	50.03	156280	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	9.739	630727	91.00	31451	bb	Unknown
2	27.855	62404	9.00	1517	bb	Unknown

5g: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-bromophenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	15.083	6705176	50.38	274903	bb	Unknown
2	17.929	6604471	49.62	238117	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	15.056	26764	0.99	1484	bb	Unknown
2	17.776	2667108	99.01	90460	bb	Unknown

5h: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-fluorophenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	12.176	55543409	55.71	1806276	bb	Unknown
2	22.429	44162198	44.29	1002608	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	12.681	3935660	90.67	169615	bb	Unknown
2	23.455	404998	9.33	11397	bb	Unknown

5i: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(4-chlorophenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	11.623	12329132	50.01	277111	bb	Unknown
2	16.412	12322472	49.99	152059	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	11.238	8583491	12.34	240183	bb	Unknown
2	15.460	60985158	87.66	765574	bb	Unknown

5j: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(thiophen-2-yl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.142	2993541	70.94	73410	bb	Unknown
2	17.020	1226225	29.06	24246	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	13.393	21830132	96.99	161961	bb	Unknown
2	17.719	677564	3.01	12688	bb	Unknown

5k: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(furan-3-yl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	13.549	4236471	54.54	107222	bb	Unknown
2	19.522	3531690	45.46	60060	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.241	274567	6.52	7263	bb	Unknown
2	20.244	3937079	93.48	63735	bb	Unknown

6a: *tert*-butyl (*S*)-((*R*)-3-benzoyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.385	14905498	49.57	542229	bb	Unknown
2	22.312	15161127	50.43	332086	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.370	15371234	21.73	569969	bb	Unknown
2	21.815	55379264	78.27	1021933	bb	Unknown

7a: *tert*-butyl (*S*)-((*R*)-3-benzoyl-2-oxotetrahydro-2*H*-pyran-3-yl)(phenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.263	9862841	48.53	397239	bb	Unknown
2	27.006	10462204	51.47	197160	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	14.783	2685478	35.34	109010	bb	Unknown
2	27.835	4913932	64.66	92670	bb	Unknown

8a: *tert*-butyl (*S*)-((*R*)-2-oxo-3-propionyltetrahydrofuran-3-yl)(phenyl)methylcarbamate





Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	5.920	9305783	50.65	619077	bb	Unknown
2	10.743	9065509	49.35	433638	bb	Unknown




Entry	Retention Time	Area	Area (%)	Height	Int Type	Peak Type
1	6.112	31783495	95.58	1924229	bb	Unknown
2	11.005	1469640	4.42	80758	bb	Unknown



8.0 Copies of NMR spectra of products.


4b: 3-benzoyldihydrofuran-2(3H)-one








4c: 3-benzoyltetrahydro-2H-pyran-2-one








4d: 3-propionyldihydrofuran-2(3H)-one








3a: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(phenyl)methyl)-2-oxocyclopentane carboxylate








3b: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(naphthalen-1-yl)methyl)-2-oxocyclopentane carboxylate








3c: (*S*)-ethyl 1-((*R*)-(tert-butoxycarbonylamino)(2-fluorophenyl)methyl)-2-oxocyclopentane carboxylate








3d: (S)-ethyl 1-((S)-(tert-butoxycarbonylamino)(3-methoxyphenyl)methyl)-2-oxocyclopentanecarboxylate








5a: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate







5b: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(p-tolyl)methylcarbamate








5c: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(o-tolyl)methylcarbamate




18






5d: *tert*-butyl ((*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-methoxyphenyl)methylcarbamate








5e: *tert*-butyl (*S*)-(*(R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(3-methoxyphenyl)methylcarbamate








5f: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(m-tolyl)methylcarbamate








5g: *tert*-butyl (*R*)-(*(R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-bromophenyl)methylcarbamate








5h: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(2-fluorophenyl)methylcarbamate








5i: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(4-chlorophenyl)methylcarbamate








5j: *tert*-butyl (*R*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(thiophen-2-yl)methylcarbamate








5k: *tert*-butyl (*S*)-((*R*)-3-acetyl-2-oxotetrahydrofuran-3-yl)(furan-3-yl)methylcarbamate








6a: *tert*-butyl (*S*)-((*R*)-3-benzoyl-2-oxotetrahydrofuran-3-yl)(phenyl)methylcarbamate





7a: *tert*-butyl (*S*)-((*R*)-3-benzoyl-2-oxotetrahydro-2*H*-pyran-3-yl)(phenyl)methylcarbamate





8a: *tert*-butyl (*S*)-((*R*)-2-oxo-3-propionyltetrahydrofuran-3-yl)(phenyl)methylcarbamate

